Sign in
AKTX Stock Price, Chart, Stats & News
Akari Therapeutics, Plc
Save
12.85M
Market cap
–
Current P/E
–
Forward P/E
AKTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 6.43% |
ROA | -34.67% |
ROE | -68.21% |
D/E | 0.09x |
Interest coverage ratio | -37.65x |
AKTX valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | 0.00x |
EV multiple | -0.02x |
About
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes.
Similar securities
Based on sector and market capitalization
Report issue